Status In progress
Process STA pre-2018
ID number 1036

Project Team

Project lead James Maskrey

Email enquiries

Evidence Review Group / Assessment Group Southampton Health Technology Assessment Centre

Consultees

Companies sponsors Amgen
Others Department of Health
  NHS England
  Welsh Assembly Government
Patient carer groups Leukaemia UK
Professional groups Royal College of Pathologists
  British Society of Haematology
  Cancer Research UK

Commentators

Comparator companies Aspen Pharma
  Jazz Pharmaceuticals
  Pfizer
General commentators Health Improvement Scotland

Timeline

Key events during the development of the guidance:

Date Update
08 May 2019 Committee meeting: 2
27 February 2019 - 27 March 2019 Appraisal consultation
15 March 2019 The next committee meeting date for the appraisal of blinatumomab for treating minimal residual B-precursor acute lymphoblastic leukaemia in remission has been rescheduled to allow the company (Amgen) additional time to provide new information requested by the committee in the ACD. The next committee meeting is now confirmed for 8 May 2019 (previously 3 April 2019).
05 February 2019 Committee meeting: 1
08 January 2019 This appraisal has been rescheduled into NICE’s work-stream and a committee meeting will take place on Tuesday 5 February 2019, in Manchester.
03 May 2018 Following on from advice received from the company this appraisal will be rescheduled to align with the latest regulatory expectations. The committee discussion will no longer take place in June 2018. We will provide a further update and new meeting date when more information is available.
13 December 2017 Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, the committee discussion will now take place in June 2018.
17 August 2017 Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, the deadline for submissions is now expected late October 2017.
06 June 2017 Invitation to participate
22 July 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance